



James Inglese, PhD

Head Assay Development & Screening Technology

*Assay Design and Library Screening Strategies Targeting Rare and Neglected Diseases*

Dr. James Inglese, Ph.D. directs the Laboratory of Assay Development and Screening Technology (ADST) within the National Center for Advancing Translational Sciences (NCATS) and is an Adjunct Investigator within the National Human Genome Research Institute (NHGRI). His laboratory explores biochemical and phenotypic-based approaches to the identification of novel chemical matter for the development of chemical probes and therapeutic leads. The NCATS post-doctoral training program he has established is recognized by disease foundations as an effective collaborative bridge to NCATS expertise and resources enabling a champion-driven effort in early stage translation. Prior to his current position he co-founded the NIH Chemical Genomics Center (NCGC), the forerunner of NCATS. Dr. Inglese received his Ph.D. in Organic Chemistry from the Pennsylvania State University and completed post-doctoral training in the laboratory Prof. Robert J. Lefkowitz at Duke University Medical Center. Before coming to the NIH, Dr. Inglese led research teams at the Princeton-based combinatorial chemistry biotech Pharmacopeia and Merck Research Laboratories. Over the past two decades, Dr. Inglese has contributed to over 180 publications and patents; his efforts on the early drug discovery process have resulted in novel assay formats, reporter systems, and high throughput screening paradigms. Dr. Inglese serves on the scientific advisory boards of several NIH-funded chemistry and screening centers, disease foundations, and international chemical biology consortia.